Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Dimitrios Vlahakos, Charalabos Vlachopoulos, Konstantinos Tziomalos, Dimitrios Tziakas, Panagiotis Vardas, Emanouel Ganotakis, Konstantinos Tsioufis, Evridiki Drogari, Christina Chrysochoou, Eleni Bilianou, Alexandra Bargiota, Vasilios Athyros, Dimitrios Alexopoulos, Theodoros Alexandrides, Apostolos Achimastos, Moses Elisaf, Ioannis Ioannidis, Alexandros Tselepis, Dimitrios Tousoulis, Nicolaos Tentolouris, Ioannis Skoumas, Dimitrios Richter, Loukianos Rallidis, Christos Pitsavos, Stavros Pappas, George Ntaios, Ioannis Goudevenos, Genovefa Kolovou, Vasilios Kotsis, Ioannis Lekakis, Evangelos Liberopoulos, Andreas Melidonis, Vasilios Nikolaou, Nikolaos Papanas
Hormones (Athens, Greece) 2017;15(1):8-14